Page 5 - காத்தாடி பார்மா இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from காத்தாடி பார்மா இன்க். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In காத்தாடி பார்மா இன்க் Today - Breaking & Trending Today

Worldwide CAR T-Cell Therapy Industry to 2030 - Players Include Legend Biotech, Novartis & Pfizer Among Others

Share this article
Share this article
ResearchAndMarkets.com s offering.
The scientific community has been pursuing research for the development of CAR T-cell therapy for over a century. Immunotherapy has emerged as an innovative treatment option over decades, as it harnesses the patient s immune system to attack cancer. The global market for CAR T-cell therapy is predicted to grow at a CAGR of 44.79% over the forecast period 2020-2030. The market is driven by certain factors, which include increasing global geriatric population, increasing number of lymphoma and leukemia cases, rising number of relapsed or refractory cancer cases showing response failure to alternative treatments such as chemotherapy and radiation therapy, focus on research and development of novel immunotherapies, and strong product pipeline of global CAR T-cell therapy. ....

United States , South Korea , Brexucabtagene Autoleucel Tecartus , Axicabtagene Ciloleucel , Tisagenlecleucel Kymriah , Idecaptagene Cicleucel , Lisocabtagene Maraleucel , Laura Wood , Axicabtagene Ciloleucel Yescarta , Kite Pharma Inca Gilead Company , Janssen Pharmaceuticals Inc , Research Scope , Bristol Myers Squibb Company , Pfizer Inc , Legend Biotech Corporation , Technology Definition , Bluebird Bio Inc , Car Therapy Development , Bellicum Pharmaceuticals Inc , Kite Pharma Inc , Custom Research , Company Overview , Carsgen Therapeutics Ltd , Office Hours Call , Cartesian Therapeutics Inc , Research Methodology ,

Novartis International AG: Novartis reports positive topline results from second Phase III trial of Beovu in patients with diabetic macular edema

Novartis International AG: Novartis reports positive topline results from second Phase III trial of Beovu in patients with diabetic macular edema
,
Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52)
1
In a secondary endpoint, more than half of Beovu patients in the 6 mg arm were maintained on a three-month dosing interval through year one, following the loading phase
1
Significant improvement with Beovu 6 mg in change of central subfield thickness (CST) from baseline over the period of week 40 through week 52 was observed
1
1
Novartis intends to submit the data from KESTREL, together with the data from the pivotal Phase III KITE ....

United States , Eric Althoff , Isabella Zinck , Dirk Sauer , Thomas Hungerbuehler , Amy Wolf , Indianj Ophthalmol , Samir Shah , Beovu Basel , Sloan Simpson , Kite Pharma Inc , Novartis Division Communications , Novartis Us External Communications , Novartis External Communications , Exchange Commission , Canadian Drug Expert Committee Recommendation , Global Head Development , National Eye Institute , National Health Insurance Pricing , Canadian Agency For Drugs , Technologies In Health , Association For Research , Novartis Pharma , Kite Pharma , Patients With Visual Impairment Due , Diabetic Macular Edema ,

Novartis reports positive topline results from second Phase III trial of Beovu in patients with diabetic macular edema

Posted December 15th, 2020 for Novartis
In Phase III KESTREL study
,
Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52)
1
In a secondary endpoint, more than half of Beovu patients in the 6 mg arm were maintained on a three-month dosing interval through year one, following the loading phase
1
Significant improvement with Beovu 6 mg in change of central subfield thickness (CST) from baseline over the period of week 40 through week 52 was observed
1
1
Novartis intends to submit the data from KESTREL, together with the data from the pivotal Phase III KITE ....

United Kingdom , United States , Eric Althoff , Isabella Zinck , Dirk Sauer , Thomas Hungerbuehler , Amy Wolf , Indianj Ophthalmol , Samir Shah , Beovu Basel , Sloan Simpson , Kite Pharma Inc , Novartis Division Communications , Novartis Us External Communications , Novartis External Communications , Exchange Commission , Canadian Drug Expert Committee Recommendation , Global Head Development , National Eye Institute , National Health Insurance Pricing , Canadian Agency For Drugs , Technologies In Health , Association For Research , Novartis Pharma , Kite Pharma , Patients With Visual Impairment Due ,

Novartis reports positive topline results from second Phase III trial of Beovu® in patients with diabetic macular edema – IT Business Net

In Phase III KESTREL study
,
Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52)
1
In a secondary endpoint, more than half of Beovu patients in the 6 mg arm were maintained on a three-month dosing interval through year one, following the loading phase
1
Significant improvement with Beovu 6 mg in change of central subfield thickness (CST) from baseline over the period of week 40 through week 52 was observed
1
1
Novartis intends to submit the data from KESTREL, together with the data from the pivotal Phase III KITE
2
study in DME, to health authorities in H1 2021 ....

United States , Eric Althoff , Isabella Zinck , Dirk Sauer , Thomas Hungerbuehler , Amy Wolf , Indianj Ophthalmol , Samir Shah , Beovu Basel , Sloan Simpson , Kite Pharma Inc , Novartis Division Communications , Novartis Us External Communications , Novartis External Communications , Exchange Commission , Canadian Drug Expert Committee Recommendation , Global Head Development , National Eye Institute , National Health Insurance Pricing , Canadian Agency For Drugs , Technologies In Health , Association For Research , Novartis Pharma , Kite Pharma , Patients With Visual Impairment Due , Diabetic Macular Edema ,